Radosevic-Robin, Nina http://orcid.org/0000-0002-1633-8730
Selenica, Pier
Zhu, Yingjie http://orcid.org/0000-0003-1849-6019
Won, Helen H.
Berger, Michael F. http://orcid.org/0000-0003-3882-5000
Ferrando, Lorenzo http://orcid.org/0000-0002-4025-7930
Cocco, Emiliano
Privat, Maud
Ponelle-Chachuat, Flora
Abrial, Catherine
Nabholtz, Jean-Marc
Penault-Llorca, Frederique
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Scaltriti, Maurizio http://orcid.org/0000-0002-5522-1447
Article History
Received: 24 January 2021
Accepted: 20 August 2021
First Online: 17 September 2021
Competing interests
: M.S. has received research funds from Puma Biotechnology, AstraZeneca, Daiichi-Sankyo, Immunomedics, Targimmune, and Menarini Ricerche, is a cofounder of Medendi.org and is on the advisory board of Menarini Ricerche. M.S. is an employee and stockholder of AstraZeneca. J.S.R.-F. is a consultant of Goldman Sachs and REPARE Therapeutics, a member of the Scientific Advisory Board of VolitionRx and Paige.AI, and an ad hoc member of the Scientific Advisory Board of Ventana Medical Systems, Roche, Genentech, Novartis, and InviCRO, outside of the scope of the submitted work. F.P.-L. has received consulting honoraria from Merck, Amgen, and Sanofi. All the other authors do not report potential conflicts of interest.